ApprovalTrail

Approval · Notice of Compliance 16483 · 2014

MAVIK: Notice of Compliance 16483

Issued December 31, 2014

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
16483
Date
December 31, 2014
Company
BGP Pharma ULCEtobicoke, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
New Drug Submission (NDS)
Submission class
Admin
Reason
Transfer of drug identification numbers
Therapeutic class
Angiotensin converting enzyme inhibitor

Products in this notice

BrandDINStatus today
MAVIK02231457Marketed
MAVIK02231459Marketed
MAVIK02231460Marketed
MAVIK02239267Marketed

Medicinal ingredients